Hanx Biopharmaceuticals Adds 26,000 H-Shares to Treasury; Outstanding Share Count Dips 0.02%

Bulletin Express05-20 19:03

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a repurchase of 26,000 H-shares on 20 May 2026, which have been retained as treasury shares. The on-market buyback was executed within a price range of HKD 28.94 to HKD 30.48 per share, translating into a volume-weighted average cost of HKD 29.47 per share and an aggregate cash outlay of HKD 0.77 million.

Post-transaction, the company’s outstanding share count (excluding treasury shares) fell to 135.48 million, down 0.02% from 135.51 million a day earlier. The total issued share capital remains unchanged at 136.22 million shares, while treasury shares increased to 735,000.

The repurchase forms part of the mandate approved on 12 February 2026, under which Hanx Biopharmaceuticals is authorised to buy back up to 13.62 million shares. Including the latest transaction, the company has repurchased 735,000 shares, representing approximately 0.54% of the issued share base on the mandate date.

In accordance with Hong Kong Listing Rules, the company is subject to a 30-day moratorium on issuing new shares or selling treasury shares, ending on 19 June 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1193769474?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-20 19:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193769474","market":"hk","top_or_hot":-1,"title":"Hanx Biopharmaceuticals Adds 26,000 H-Shares to Treasury; Outstanding Share Count Dips 0.02%","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a repurchase of 26,000 H-shares on 20 May 2026, which have been retained as treasury shares. The on-market buyback was executed within a price range of HKD 28.94 to HKD 30.48 per share, translating into a volume-weighted average cost of HKD 29.47 per share and an aggregate cash outlay of HKD 0.77 million.</p>\n<p>Post-transaction, the company’s outstanding share count (excluding treasury shares) fell to 135.48 million, down 0.02% from 135.51 million a day earlier. The total issued share capital remains unchanged at 136.22 million shares, while treasury shares increased to 735,000.</p>\n<p>The repurchase forms part of the mandate approved on 12 February 2026, under which Hanx Biopharmaceuticals is authorised to buy back up to 13.62 million shares. Including the latest transaction, the company has repurchased 735,000 shares, representing approximately 0.54% of the issued share base on the mandate date.</p>\n<p>In accordance with Hong Kong Listing Rules, the company is subject to a 30-day moratorium on issuing new shares or selling treasury shares, ending on 19 June 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hanx Biopharmaceuticals Adds 26,000 H-Shares to Treasury; Outstanding Share Count Dips 0.02%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHanx Biopharmaceuticals Adds 26,000 H-Shares to Treasury; Outstanding Share Count Dips 0.02%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-20 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a repurchase of 26,000 H-shares on 20 May 2026, which have been retained as treasury shares. The on-market buyback was executed within a price range of HKD 28.94 to HKD 30.48 per share, translating into a volume-weighted average cost of HKD 29.47 per share and an aggregate cash outlay of HKD 0.77 million.</p>\n<p>Post-transaction, the company’s outstanding share count (excluding treasury shares) fell to 135.48 million, down 0.02% from 135.51 million a day earlier. The total issued share capital remains unchanged at 136.22 million shares, while treasury shares increased to 735,000.</p>\n<p>The repurchase forms part of the mandate approved on 12 February 2026, under which Hanx Biopharmaceuticals is authorised to buy back up to 13.62 million shares. Including the latest transaction, the company has repurchased 735,000 shares, representing approximately 0.54% of the issued share base on the mandate date.</p>\n<p>In accordance with Hong Kong Listing Rules, the company is subject to a 30-day moratorium on issuing new shares or selling treasury shares, ending on 19 June 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1193769474","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193769474","pubTimestamp":1779275015,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a repurchase of 26,000 H-shares on 20 May 2026, which have been retained as treasury shares. The on-market buyback was executed within...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"汉克斯生物制药增持2.6万股H股入库；流通股数量下降0.02%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a repurchase of 26,000 H-shares on 20 May 2026, which have been retained as treasury shares. The on-market buyback was executed within a price range of HKD 28.94 to HKD 30.48 per share, translating into a volume-weighted average cost of HKD 29.47 per share and an aggregate cash outlay of HKD 0.77 million.\nPost-transaction, the company’s outstanding share count (excluding treasury shares) fell to 135.48 million, down 0.02% from 135.51 million a day earlier. The total issued share capital remains unchanged at 136.22 million shares, while treasury shares increased to 735,000.\nThe repurchase forms part of the mandate approved on 12 February 2026, under which Hanx Biopharmaceuticals is authorised to buy back up to 13.62 million shares. Including the latest transaction, the company has repurchased 735,000 shares, representing approximately 0.54% of the issued share base on the mandate date.\nIn accordance with Hong Kong Listing Rules, the company is subject to a 30-day moratorium on issuing new shares or selling treasury shares, ending on 19 June 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1193769474","isCrawlerRequest":true}